A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

Official record

Identifier

NCT07752875

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

LG00313112

Lead sponsor

LG Chem

Target enrolment

250 participants

Study type

INTERVENTIONAL

Phase

Phase 1/2

Status

Not yet recruiting

First posted

Aug 7, 2026

Last updated on the registry

Aug 7, 2026

Age

18 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Males and females aged 18 years or older
2. Diagnosed locally advanced unresectable or metastatic solid tumor with a TP53 Y220C mutation.
3. Documented disease progression during or after the most recent line of therapy. In addition, must be refractory to or intolerant of standard of care therapy or have no standard therapy.
4. Measurable disease per RECIST v1.1.
5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
6. Adequate organ function.

Exclusion Criteria:

1. Investigational therapy or anti-cancer therapy within 21 days or 5 half-lives prior to the first dose of study drug.
2. Radiotherapy within 14 days prior to the first dose of study drug.
3. Known brain metastases (Exception: Brain metastases are permitted if the participant is neurologically stable), leptomeningeal disease or carcinomatous meningitis.
4. Uncontrolled pleural effusion, pericardial effusion, or ascites.
5. History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
6. Serious infections requiring intravenous antibiotics within 14 days of first dose of study drug.
7. Active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection
8. Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease
9. History of prior organ transplant
10. Currently receiving strong Cytochrome P4503A (CYP3A4) inhibitors or inducers

Indexed under

Esophageal Cancer